This clinical trial is focused on studying a condition called anemia, which is a situation where the body does not have enough healthy red blood cells to carry oxygen. Specifically, the trial is looking at anemia caused by a group of blood disorders known as lower-risk myelodysplastic syndromes (LR-MDS). These syndromes affect the bone marrow and can lead to a shortage of blood cells. The treatment being tested in this study is a medication called AG-946, which is taken as a coated tablet by mouth.

The purpose of the study is to explore how effective and safe AG-946 is for people with anemia due to LR-MDS. The study is divided into two phases. In the first phase, researchers aim to see if the treatment shows promise in helping patients. In the second phase, they will look at whether the treatment can help patients become independent of blood transfusions, meaning they won’t need transfusions for a certain period. Participants will take the medication for a maximum of 180 days, and their health will be monitored throughout the study.

Some participants will receive the actual medication, while others may receive a placebo. The study will help determine if AG-946 can improve the condition of those with LR-MDS by increasing their hemoglobin levels, which is a protein in red blood cells that carries oxygen. The trial will also assess any side effects or changes in the participants’ health during the study period. This research is important for finding new ways to manage anemia in people with LR-MDS.